Article Text

Download PDFPDF
CD39 deletion in TCR-engineered T cells enhances antitumour immunity
  1. Alexander K Tsai,
  2. Ingunn M Stromnes
  1. Microbiology & Immunology, University of Minnesota, Minneapolis, Minnesota, USA
  1. Correspondence to Dr Ingunn M Stromnes, Microbiology & Immunology, University of Minnesota Medical School, Minneapolis, Minnesota, USA; ingunn{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Tumour-reactive T cells infiltrating solid tumours are often rendered exhausted, a cell differentiation state characterised by upregulation of inhibitory receptors and reduced effector function. The process of T-cell exhaustion permits cancer progression and interferes with immunotherapy response. Efforts to overcome T-cell exhaustion, such as immune checkpoint blockade (ICB), can lead to remarkable clinical responses in some patients with cancer. However, only a minority of patients respond to ICB, responses often lack durability, and undesirable immune-related toxicities are prevalent. Thus, elucidating additional factors that limit T-cell function in cancer may reveal new therapeutic targets to safely promote tumour eradication.

While persistent T-cell receptor (TCR) signalling due to chronic tumour antigen is a major driver of exhaustion, the suppressive tumour microenvironment (TME) also contributes.1 Over the last two decades, the ectoenzymes CD39 and CD73, which degrade extracellular ATP to adenosine, have been implicated in T-cell exhaustion.2 3 In cancer, stressed or damaged cells release ATP. Subsequently, CD39 and CD73 work in concert to convert extracellular ATP to adenosine, which has broad immunosuppressive effects.2 3 In T cells, adenosine regulates proximal TCR signalling events, thereby reducing T-cell effector function. CD39 is highly expressed on exhausted T cells found in human cancers4 5 and cancer or persistent viral infection mouse models.6–8

Here, Potenza et al9 investigate the phenotypic traits of human T cells infiltrating colorectal cancer (CRC) tumours and metastases. Using transcriptional profiling, flow cytometry and …

View Full Text


  • Twitter @IngunnStromnes

  • Contributors AKT and IMS cowrote the commentary.

  • Funding AKT is supported by NIH T32CA009138-48. IMS is supported by NIH R01 CA254849, CA249393, R01 CA255039, U54 CA268069, P01 CA254849, DOD W81XWH2110525, an AACR Pancreatic Cancer Action Network Catalyst Award (19-35-STRO) and American Cancer Society RSG-21-102-01-IBCD.

  • Competing interests IMS serves on scientific advisory boards for Immunogenesis and Luminary Therapeutics and has patents in TCR engineering approaches, not directly related to this commentary.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles

  • Colon
    Alessia Potenza Chiara Balestrieri Martina Spiga Luca Albarello Federica Pedica Francesco Manfredi Beatrice Claudia Cianciotti Claudia De Lalla Oronza A Botrugno Cristina Faccani Lorena Stasi Elena Tassi Silvia Bonfiglio Giulia Maria Scotti Miriam Redegalli Donatella Biancolini Barbara Camisa Elena Tiziano Camilla Sirini Monica Casucci Chiara Iozzi Danilo Abbati Fabio Simeoni Dejan Lazarevic Ugo Elmore Guido Fiorentini Giulia Di Lullo Giulia Casorati Claudio Doglioni Giovanni Tonon Paolo Dellabona Riccardo Rosati Luca Aldrighetti Eliana Ruggiero Chiara Bonini